Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of ProSavin in Parkinson's Disease
NCT01856439Phase 2Terminated
- Sponsor
- Sio Gene Therapies
- Start
- May 2011
- Primary completion
- Nov 2021
- Modality
- Gene Editing, Gene Silencing, Lentiviral Vectors
- Countries
- 2
01
Overview
A Phase 2 trial of ProSavin in Parkinson's disease (PD), sponsored by Sio Gene Therapies. Started May 2011; status: terminated.
02
Drugs
ProSavin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01856439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856439.